Early Detection of Cardiac Damage

Doxorubicin remains a cornerstone of chemotherapy, but its potential for cumulative, dose-dependent heart damage often restricts clinical use. Because standard tests like troponin lack sensitivity for the earliest stages, finding reliable anthracycline cardiotoxicity biomarkers is a top priority for clinicians. Specifically, researchers recently used an animal model to explore the heart's protein landscape. Furthermore, they employed SWATH-MS proteomics to identify subtle changes. Consequently, this approach revealed critical signals before functional decline occurred. Therefore, these findings might help doctors protect patients' hearts more effectively and choose alternative treatments sooner.

Shortlisting New Anthracycline Cardiotoxicity Biomarkers

First, the study compared the myocardial proteome of doxorubicin-treated rats against controls over several weeks. Second, the investigators focused on proteins with sustained dysregulation. Notably, they identified 34 candidate proteins as potential anthracycline cardiotoxicity biomarkers. For example, myosin light chain 3 and desmin showed early and consistent changes throughout the dosing schedule. In addition, cysteine-rich protein 2 appeared as a significant early indicator of myocardial stress. Moreover, pathway analysis showed that these proteins are involved in muscle structure, metal ion regulation, and inflammation. However, although these results are promising, human validation is still required. Ultimately, this proteomic map provides a clear path for future diagnostic development. Thus, clinicians may soon have better tools for early intervention. Additionally, the study successfully recapitulated the dosing schedules seen in human patients. Indeed, these 34 candidates represent a major step forward in cardio-oncology research.

Frequently Asked Questions

Why are new biomarkers needed beyond troponin?

Troponin and NT-proBNP are useful but often rise only after significant myocardial damage has occurred. Because of this, new biomarkers aim to detect subclinical cellular changes that precede functional decline.

What is SWATH-MS in the context of this study?

SWATH-MS is a high-resolution proteomics method. Specifically, it identifies and quantifies thousands of proteins simultaneously. This provides a comprehensive view of how the heart's protein landscape shifts during drug treatment.

What are the top protein candidates identified?

The study highlighted myosin light chain 3, desmin, and cysteine-rich protein 2. Notably, these proteins showed significant changes at early, mid, and late timepoints during the treatment cycle.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Shotton R et al. SWATH-MS for discovery of early biomarkers of drug-induced cardiotoxicity using an animal doxorubicin model. Cardiooncology. 2026 May 13. doi: 10.1186/s40959-026-00484-0. PMID: 42121005.

Camilli M, Cipolla CM, Dent S, Minotti G, Cardinale DM. Anthracycline Cardiotoxicity in Adult Cancer Patients: JACC: CardioOncology State-of-the-Art Review. JACC CardioOncol. 2024;6(5):655-677.

Feng W, Wang Q, Tan Y, et al. Early detection of anthracycline-induced cardiotoxicity. Clin Chim Acta. 2025;565:120000. doi: 10.1016/j.cca.2024.120000.